vTv Therapeutics Inc. (NASDAQ:VTVT) shares shot up 6.9% during trading on Wednesday . The stock traded as high as $6.10 and last traded at $5.88, with a volume of 92,842 shares traded. The stock had previously closed at $5.50.

Separately, Zacks Investment Research downgraded shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $16.80.

The stock has a 50-day moving average of $5.75 and a 200-day moving average of $5.85. The company’s market cap is $59.01 million.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.12. Analysts forecast that vTv Therapeutics Inc. will post ($2.63) earnings per share for the current year.

In related news, Director Paul G. Savas acquired 6,000 shares of the stock in a transaction dated Friday, May 27th. The stock was bought at an average price of $5.67 per share, with a total value of $34,020.00. Following the completion of the transaction, the director now directly owns 58,781 shares of the company’s stock, valued at $333,288.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.